Table 1 |
||||||
| Demographic and clinical characteristics | ||||||
| IADL | PSMS | |||||
| Improved/ unchanged | Deteriorated | Pvalue | Improved/ unchanged | Deteriorated | Pvalue | |
| Variable | n = 383 (49%) | n = 401 (51%) | n = 578 (74%) | n = 206 (26%) | ||
| Female gender | 232 (61%) | 264 (66%) | 0.138 | 360 (62%) | 136 (66%) | 0.356 |
| APOE ε4 carrier, (n=771) | 257 (68%) | 268 (68%) | 1.000 | 387 (68%) | 138 (68%) | 1.000 |
| Solitary living at baseline | 116 (30%) | 141 (35%) | 0.149 | 184 (32%) | 73 (35%) | 0.343 |
| Antihypertensives/Cardiac therapy | 156 (41%) | 158 (39%) | 0.716 | 237 (41%) | 77 (38%) | 0.407 |
| Anti-diabetics | 19 (5%) | 14 (3%) | 0.374 | 29 (5%) | 4 (2%) | 0.068 |
| Lipid-lowering agents | 46 (12%) | 39 (10%) | 0.358 | 65 (11%) | 20 (10%) | 0.603 |
| Estrogens | 21 (5%) | 35 (9%) | 0.095 | 37 (6%) | 19 (9%) | 0.206 |
| NSAIDs/Acetylsalicylic acid | 116 (30%) | 117 (29%) | 0.755 | 173 (30%) | 60 (29%) | 0.929 |
| Anti-depressants | 91 (24%) | 107 (27%) | 0.366 | 131 (23%) | 67 (33%) | 0.007 |
| Anti-psychotics | 11 (3%) | 20 (5%) | 0.145 | 20 (3%) | 11 (5%) | 0.296 |
| Anxiolytics/Sedatives/Hypnotics | 54 (14%) | 51 (13%) | 0.601 | 70 (12%) | 35 (17%) | 0.094 |
| Variable | Mean ± standard deviation | Pvalue | Mean ± standard deviation | Pvalue | ||
| Estimated age at onset, years | 71.8 ± 7.2 | 71.9 ± 7.7 | 0.969 | 71.5 ± 7.7 | 72.9 ± 6.8 | 0.023 |
| Age at first assessment, years | 74.8 ± 7.1 | 75.0 ± 7.1 | 0.678 | 74.6 ± 7.4 | 76.0 ± 6.3 | 0.007 |
| Education, years | 9.3 ± 2.4 | 9.4 ± 2.5 | 0.388 | 9.4 ± 2.5 | 9.3 ± 2.5 | 0.755 |
| MMSE score at baseline | 21.6 ± 3.8 | 21.1 ± 3.8 | 0.116 | 21.8 ± 3.5 | 20.0 ± 4.1 | <0.001 |
| ADAS-cog score (0–70) at baseline | 20.0 ± 8.9 | 21.4 ± 8.9 | 0.030 | 19.5 ± 8.5 | 24.1 ± 9.1 | <0.001 |
| IADL score at baseline | 16.4 ± 5.9 | 15.3 ± 4.8 | 0.005 | 15.1 ± 5.3 | 18.1 ± 5.1 | <0.001 |
| PSMS score at baseline | 7.5 ± 2.2 | 7.5 ± 2.1 | 0.969 | 7.4 ± 2.1 | 7.7 ± 2.3 | 0.113 |
| Number of medications at baseline | 3.0 ± 2.5 | 2.7 ± 2.3 | 0.216 | 2.8 ± 2.4 | 3.1 ± 2.4 | 0.101 |
ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale, APOE apolipoprotein E, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental State Examination, NSAID non-steroidal anti-inflammatory drugs, PSMS Physical Self-Maintenance Scale.
Wattmo et al. BMC Neurology 2012 12:134 doi:10.1186/1471-2377-12-134
